09:22 AM EDT, 07/10/2025 (MT Newswires) -- Moderna ( MRNA ) said Thursday it has received US Food and Drug Administration approval for its supplemental biologics license application for COVID-19 vaccine Spikevax in children aged six months to 11 years who have a high risk of COVID-19 disease.

The company said it expects to have its updated Spikevax vaccine available for eligible populations in the US for the 2025-2026 respiratory virus season.

Moderna ( MRNA ) shares were up more than 3% in recent Thursday premarket activity.